ArticleOncotarget2016
Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 39 citations in OpenAlex.
- Breast cancer in previously thyroidectomized patients: which thyroid disorders are a risk factor?Future science OA · 2021Trial
- Article
- Spatial concordance patterns of breast and thyroid cancer based on burden inequalities and related risk factors analyses.Gland surgery · 2026Article
- Development and validation of a multifactorial risk prediction model for breast cancer patients with co-occurring thyroid cancer: a retrospective matched case-control study.Frontiers in oncology · 2026Article
- Metabolic Risk Factors at the Time of Cancer Diagnosis in Primary Care: A Cross-Sectional Study.Cureus · 2025Article
- Decoding the mechanisms behind second primary cancers.Journal of translational medicine · 2025Review
- Risk Factors and Prognostic Implications in Synchronous Breast-Thyroid Dual Primary Cancers: A Matched Case-Control Study.Cancer management and research · 2025Article
- Association Between a History of Breast Cancer and Decreased Thyroid Cancer-specific Mortality.The Journal of clinical endocrinology and metabolism · 2024Article
- Characteristics and survival analysis of breast cancer survivors with metachronous double primary cancers: a retrospective cohort study.Translational cancer research · 2023Article
- The clinical and genetic features in patients coexisting primary breast and thyroid cancers.Frontiers in endocrinology · 2023Article
- Clinical characteristics and survival of glioblastoma complicated with non-central nervous system tumors.Chinese neurosurgical journal · 2022Article
- The co-occurrence of both breast- and differentiated thyroid cancer: incidence, association and clinical implications for daily practice.BMC cancer · 2022Article
- A Descriptive Study of the Types and Survival Patterns of Saudi Patients with Multiple Primary Solid Malignancies: A 30-Year Tertiary Care Center Experience.Current oncology (Toronto, Ont.) · 2022Article
- Synchronous Hürthle cell and medullary thyroid carcinomas.BMJ case reports · 2022Article
- Article
- Case report: Lymph node metastases of breast cancer and thyroid cancer encountered in axilla.Frontiers in oncology · 2022Article
- Time Intervals between Double Primary Breast and Ovarian Cancers and Survival Outcomes of Patients with Both Cancers: A SEER Database Analysis.BioMed research international · 2022Article
- Article
- Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective study.BMC cancer · 2021Article
- The clinical value ofQuantitative imaging in medicine and surgery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical experiences suggest that breast cancer (BC) and thyroid cancer (TC) occur metachronously or synchronously in a patient more frequently than it would by chance. This study was conducted to investigate the clinicopathological characteristics and survival of these double primary malignancies.
methods18732 patients with first primary BC and 12877 female patients with first primary TC were performed in this retrospective case-controlled study. The control groups were matched with both age at diagnosis and time of surgery (±2 years). The clinicopathological factors, Overall survival (OS), and HRs were evaluated by SPSS.
resultsThere were 91(0.49%) BC patients developed metachronous second primary TC (B-T group), and 117 (0.91%) TC patients developed metachronous second primary BC (T-B group).The expression of estrogen and progesterone receptors, and the value of Ki-67, were significantly higher in the B-T group than control. The median value of thyroid globulin antibody (TGAb) and thyroid peroxidase antibody (TPOAb) were higher in T-B group than control (p <0.05). The duration before second primary cancer was shorter for the B-T group than the T-B group (4.09 years vs. 5.82 years, p<0.001). B-T group patients showed poorer survival than BC only patients (p=0.044).
conclusionsIn general, the overall risk of the occurrence of a second primary TC or BC elevated highly in patients with BC or TC. Detailed mechanisms need to be studied to explore the association between these two cancers. Early detection and effective prevention for the first primary BC or TC patients are necessities for reducing the incidence of the second primary cancer and improving the OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.